Form 4: FATE CFO Adawi Awarded 25K RSUs, 75K Stock Options

FATE Therapeutics' Chief Financial Officer, Kamal Adawi, was granted 25,000 restricted stock units and options to purchase 75,000 shares of common stock.

Summary

• Kamal Adawi, Chief Financial Officer of FATE Therapeutics Inc. (FATE), was awarded 25,000 restricted stock units (RSUs) on January 15, 2026.
• These RSUs vest with respect to 1/4th of the units on each of January 8, 2027, January 8, 2028, January 8, 2029, and January 8, 2030, contingent on continued service.
• Each RSU represents a contingent right to receive one share of the Issuer's common stock upon settlement.
• Adawi was also granted options to purchase 75,000 shares of common stock on January 15, 2026, with an exercise price of $1.05 per share.
• The stock options will vest in 36 equal monthly installments following January 1, 2026, becoming fully vested and exercisable on January 1, 2029, subject to continued service.
• Following these transactions, Kamal Adawi beneficially owns 100,000 shares of common stock and 75,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of significant equity awards to the Chief Financial Officer is a positive signal for executive retention and aligns management's long-term interests with shareholder value, reflecting standard compensation practices. It does not, however, provide direct insight into operational performance or new strategic initiatives.

Positives

• The grant of restricted stock units and stock options to the Chief Financial Officer aligns management's long-term interests with those of shareholders, incentivizing sustained performance.
• Equity compensation is a standard practice for executive retention and motivation in the biotechnology industry.

Future Outlook

The equity awards, with vesting schedules extending through 2030 for RSUs and fully vesting by 2029 for options, indicate a long-term incentive structure designed to retain the Chief Financial Officer and align his performance with the company's sustained growth and shareholder value creation over several years.

Industry Context

Equity compensation, including restricted stock units and stock options, is a widely adopted practice in the biotechnology and pharmaceutical industries. It serves as a critical tool for attracting, retaining, and motivating key executives by linking their personal financial success directly to the long-term performance and stock price appreciation of the company. This grant to the CFO is consistent with typical executive compensation strategies in the sector.

Comparison to Industry Standards

• The structure of this equity grant, involving both RSUs and stock options with multi-year vesting schedules, is a standard compensation practice for executive-level positions in the biotechnology industry.
• Companies like Amgen, Gilead Sciences, and Biogen frequently utilize similar long-term incentive plans to align executive interests with shareholder value, although the specific number of units and exercise prices vary based on company size, executive role, and market conditions.

Related Party Transactions

• Grant of 25,000 restricted stock units and options to purchase 75,000 shares of common stock to Chief Financial Officer Kamal Adawi as part of his executive compensation package.

Stakeholder Impact

• Shareholders: The equity awards are designed to align the CFO's financial incentives with long-term shareholder value creation, potentially leading to more focused management decisions aimed at increasing stock price.
• Employees (CFO): Kamal Adawi receives significant long-term equity incentives, enhancing his compensation and providing a strong motivation for continued service and performance.

Next Steps

• Kamal Adawi's continued service with FATE Therapeutics Inc. is required for the vesting of both the restricted stock units and stock options.
• Upon vesting, the restricted stock units will convert into shares of common stock.
• Upon vesting, the stock options will become exercisable, allowing Kamal Adawi to purchase shares at the specified exercise price of $1.05 per share.

Key Dates

Recommendation

This Form 4 reports a routine equity compensation grant to the CFO, which is a standard practice for executive retention and incentive alignment. It does not provide new information regarding the company's operational performance, financial health, or strategic direction that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate, maintaining existing positions based on broader company fundamentals.

Keywords

FATE Therapeutics, FATE, Kamal Adawi, CFO, Restricted Stock Units, RSUs, Stock Options, Equity Compensation, Insider Transaction, Form 4